Reviewing Paradigm Medical Industries (OTCMKTS:PDMI) and LENSAR (NASDAQ:LNSR)

Paradigm Medical Industries (OTCMKTS:PDMI) and LENSAR (NASDAQ:LNSR) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.

Analyst Ratings

This is a summary of recent ratings and price targets for Paradigm Medical Industries and LENSAR, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Paradigm Medical Industries	0	0	0	0	0.00
LENSAR	0	0	1	0	3.00

LENSAR has a consensus target price of $8.00, suggesting a potential downside of 7.51%. Given Paradigm Medical Industries’ higher possible upside, equities research analysts plainly believe Paradigm Medical Industries is more favorable than LENSAR.

Volatility and Risk

Paradigm Medical Industries has a beta of -0.46, suggesting that its share price is 146% less volatile than the S&P 500. Comparatively, LENSAR has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500.

Institutional and Insider Ownership

40.2% of LENSAR shares are owned by institutional investors. 11.1% of Paradigm Medical Industries shares are owned by insiders. Comparatively, 38.5% of LENSAR shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Paradigm Medical Industries and LENSAR’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Paradigm Medical Industries	N/A	N/A	N/A
LENSAR	-34.03%	-49.02%	-21.12%

Valuation & Earnings

This table compares Paradigm Medical Industries and LENSAR”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Paradigm Medical Industries	N/A	N/A	N/A	N/A	N/A
LENSAR	$48.87 million	2.06	-$14.38 million	($1.46)	-5.92

Paradigm Medical Industries has higher earnings, but lower revenue than LENSAR.

Summary

LENSAR beats Paradigm Medical Industries on 6 of the 10 factors compared between the two stocks.

About Paradigm Medical Industries

Paradigm Medical Industries, Inc. develops, manufactures, sells, and markets medical devices for the early detection of glaucoma and other eye disorders in the United States. The company offers P-2000 biometric analyzer A-scans and P-2500 A-scans/pachymeters; P2700 A/B and P37-II A/B scans; blood flow analyzers for the detection and management of glaucoma and other retinal vascular disorders; P2200 pachymeter and P-2500 A-scan/pachymeters; and LD 500 and LD700 autoperimeters. It also provides corneal topographers, such as PARAVUE 300 for diagnostic and contact lens applications, as well as SURVEYOR 500 for cornea and anterior segment; PARAMAX, which analyzes the functionality of ganglion cells and identifies glaucoma suspects; P60 and P60 ACI ultrasound biomicroscopes; and PARACAM 1000, a non-contact endothelial microscope, as well as software and accessories. The company was founded in 1989 and is based in Salt Lake City, Utah.

About LENSAR

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.